Chicago/February 1, 2023 — Dimension Inx, a biomaterials company, announced they closed a $12M Series A Round. The round was led by Prime Movers Lab (PML), with participation by returning investors KdT Ventures and Revolution’s Rise of the Rest Seed Fund (ROTR). New investors participating in the round include Solas BioVentures, Portal Innovation Ventures, and Alumni Ventures.
Dimension Inx is a biomaterials platform that designs, develops, and manufactures therapeutic products. Enabling a new generation of regenerative therapeutics, Dimension Inx’s platform engineers three-dimensional microenvironments that direct cell behavior and allow the body to restore tissue and organ function more effectively.
The Chicago-based company will use the funding to advance the development of their therapeutics focused on functional organ restoration, and expand their manufacturing capabilities. In the near term, the company will use the funds to support the commercial launch of their first product, CMFlex™.
“We pride ourselves in catalyzing a step function change to unlock the full potential of regenerative therapeutics to cure complex disease, and we’re grateful to do so with the support of our investors,” stated CEO of Dimension Inx, Caralynn Nowinski Collens, M.D. “Our approach has always focused on the entire tissue microenvironment. If we provide the right blueprint, we make it possible to recruit the body’s natural strengths and accelerate the repair, regeneration, and ultimately, restoration of critical body function.”
“Dimension Inx represents the type of breakthrough science we believe will transform their industry and reshape our physical world,” said Prime Movers Lab Venture Partner Amy Kruse, Ph.D. who will be joining the company’s board. “We’re excited to support Dimension Inx as they enter this next phase of growth and development, and bring their transformative products to market.”
In addition to their Series A funding, Dimension Inx also announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance for CMFlex™, the first 3D-printed regenerative bone graft product cleared by the FDA. As a ready-to-use flexible ceramic for oral and maxillo-facial indications, CMFlex improves clinician workflow and reduces surgical case time for clinicians, while restoring healthy bone.
“FDA clearance is a major milestone for our platform, and validates the work we’ve put into developing our product over the past two years,” said Dr. Collens. “CMFlex is a product that represents our unique approach to restoring functionality in the body: it’s a dynamic collaboration between biology, material composition, microstructure, and macroarchitecture. We’re excited by the interest we’ve already received from surgeons who recognize the importance of a ready-to-use solution that is easy to handle and accelerates healing to improve patient outcomes.”
